We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Fed Circuit: ‘Safe Harbor’ Provision Is Broad: Amphastar, Momenta Dispute
Fed Circuit: ‘Safe Harbor’ Provision Is Broad: Amphastar, Momenta Dispute
August 14, 2012
A 2–1 final federal appeals court decision that lifts an injunction barring Watson Pharmaceuticals and Amphastar from selling a generic version of Sanofi’s blockbuster blood-thinner Lovenox hinged on an expansive interpretation of Hatch-Waxman’s “safe harbor” provision — a move that could have wide-ranging implications for all patent holders, warns Momenta Pharmaceuticals, which lost its appeal.